Non-Invasive Aesthetic Treatment Market Analysis Forecast Report 2024-2032

0 25 5 minutes read

Non-Invasive Aesthetic Treatment Market Analysis

Renub Research Market experts project the non-invasive aesthetic treatment market to grow to US$ 220.84 billion by 2032 from US$ 65.65 billion in 2023, with a CAGR of 14.3% from 2024 to 2032.

A non-invasive approach is a form of treatment that doesn’t require surgical procedures or the removal of tissues. In today’s cutting-edge Generation, many people are concerned about the signs and symptoms of growing older, such as age spots, sagging skin, and wrinkles across the mouth or eyes. Numerous non-invasive beauty approaches can be used to reduce these outcomes. Everyday non-invasive cosmetic products include peels, hyaluronic acid, and botulinum toxin. Today, patients regularly choose over-the-counter cosmetics rather than topical ones because of lower cost, shorter recovery instances, no scarring, and a reduced chance of side effects.

Request a free sample copy of the report: https://www.renub.com/non-invasive-aesthetic-treatment-market-p.php

Growth Driver of Non-Invasive Aesthetic Treatment Market

Rising Demand for Minimally Invasive Procedures: The increasing preference for treatments that offer aesthetic improvement with minimal downtime and lower risk than surgical options is fueling the market. Non-invasive procedures, such as laser therapies, injectables, and skin rejuvenation techniques, provide effective results with fewer side effects and faster recovery times. This appeal to individuals seeking cosmetic enhancements without the commitment and risks of surgery drives the demand for non-invasive aesthetic treatments, contributing significantly to market growth as more people opt for these convenient and safer alternatives.

Technological Advancements: Innovations in non-invasive technologies like laser treatments, radiofrequency, and ultrasound enhance aesthetic procedures’ effectiveness and safety. These advancements target skin concerns like wrinkles, cellulite, and skin tightening with minimal discomfort and downtime. Patients are increasingly drawn to these technologies for their ability to deliver noticeable results without the risks associated with traditional surgeries. This trend drives the adoption of non-invasive aesthetic treatments as more individuals seek safer and more effective solutions to enhance their appearance and address aging concerns. In August 2020, Lumenis Ltd introduced the NuEra Tight with FocalRF technology, a unique non-invasive treatment. Additionally, Alma Lasers launched the Harmony XL Pro in 2020, offering various non-invasive aesthetic treatments, including acne treatment, hair removal, and skin rejuvenation using advanced IPL technology.

Growing Awareness and Acceptance: Enhanced awareness about the benefits of non-invasive treatments and broader societal acceptance of aesthetic procedures encourage more individuals to seek these options. The widespread use of social media in today’s society has significantly increased the importance of physical appearance in both social and professional contexts. Video calls have become a standard interaction method, emphasizing individuals presenting themselves visually in the best possible way. Furthermore, the media’s focus on appearance has heightened beauty standards, exemplified through celebrities, movies, and fashion advertisements. Consequently, many individuals, notably those from the millennial and Generation Z demographics, seek non-surgical means to enhance their looks and achieve their desired aesthetic. In 2022, 18,857,311 non-surgical aesthetic procedures were performed globally. The most popular procedures were botulinum toxin and hyaluronic acid, with 9,221,419 and 4,312,037 procedures, respectively. Additionally, there was a significant increase in non-surgical hair removal procedures, with 1,798,253 procedures in 2022 compared to 916,869 in 2018.

North America Non-Invasive Aesthetic Treatment Market:

North America has the largest market share for non-invasive aesthetic treatments, and it is expected to continue dominating due to improved facilities, increased demand, and a growing senior population. Advanced medical devices and well-established healthcare infrastructure also drive the market growth. Factors contributing to this dominance include high disposable income, a rapidly aging population, and increased emphasis on aesthetic appearance. The significant presence of numerous skilled plastic surgeons and the increasing use of advanced treatments are also substantial contributors. According to the International Society of Aesthetic Plastic Surgery, there were approximately 7,000 plastic surgeons in the US as of 2019. These factors have resulted in the North American region’s strong position in the global non-invasive aesthetic treatment market.

Asia Pacific Non-Invasive Aesthetic Treatment Market

The Asia-Pacific region is poised for significant growth, driven by an increasing disposable income and improving living standards. This trend will lead to higher consumer expenditure on non-invasive aesthetic procedures. Additionally, a growing awareness of non-invasive treatments and a preference for Western beauty ideals contribute to the region’s demand for such procedures. According to the United Nations, it is projected that approximately 80% of the global elderly population will be residing in low- and middle-income countries by 2050. As a result, the Asia-Pacific region presents lucrative growth opportunities for market participants. Furthermore, the changing gender ratio is expected to encourage the adoption of aesthetic procedures among women in the Asia-Pacific region. The increasing consumer focus on aesthetic appearances is driving the expansion of the non-invasive aesthetic treatment market in the Asia-Pacific region.

Non-Invasive Aesthetic Treatment Company Analysis

Major global breast implant industry companies include Johnson & Johnson, Bausch Health Companies Inc., Cutera Inc., AbbVie Inc., Sisram Medical Ltd, Galderma S.A., Sientra Inc., and Revance Therapeutics Inc.

Non-Invasive Aesthetic Treatment Market Company News:

Feb 2024: AMP has launched Plasmage, the first fractional plasma device. This device offers clinicians precise control over wrinkles, crepey skin, delicate facial and body skin, and dermatological conditions like fibromas, skin tags, and xanthelasma.

January 2024: The medical aesthetics platform Empower Aesthetics has announced a collaboration with AW Skin Co. and DermaTouch RN.

January 2022: Galderma has completed its acquisition of ALASTIN Skincare®, Inc. and has obtained antitrust approval from US regulators.

January 2021: Candela introduced the Frax Pro system, the first FDA-approved non-ablative fractional device to resurface dual-depth skin. It features the Frax 1940 and Frax 1550 applicators.

Procedure– Market breakup in 3 viewpoints:

Injectables
Skin Rejuvenation
Others

Injectables- Market breakup in 4 viewpoints:

Botulinum Toxin
Hyaluronic Acid
Calcium Hydroxylapatite
Poly-L-Lactic Acid

Skin Rejuvenation- Market breakup in 4 viewpoints:

Photo Rejuvenation
Chemical peel
Micro Ablative Resurfacing
Full field Ablative

Others- Market breakup in 2 viewpoints:

Hair Removal
Non Surgical Fat Reduction

Gender- Market breakup in 2 viewpoints:

Male
Female

End User– Market breakup in 2 viewpoints:

Hospital/surgery centre
Medspa
Traditional Spa
HCP Owned Clinic

Country – Market breakup of 17 Countries:

United States
Brazil
Japan
Mexico
Turkey
Germany
Argentina
Italy
Colombia
India
Spain
Greece
Iran
Romania
United Kingdom
Thailand
Rest of the world

All the key players have been covered from 4 Viewpoints:

Business Overview
Product Portfolio
Recent Development & Strategies
Revenue Analysis

Key Players Analysis:

Johnson & Johnson
Bausch Health Companies Inc.
Cutera Inc.
AbbVie Inc.
Sisram Medical Ltd.
Galderma S.A
Sientra Inc.
Revance Therapeutics Inc.

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.